Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - H-CYTE, INC. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): August 29, 2017
MEDOVEX CORP.
(Exact Name of
Registrant as Specified in Charter)
Nevada
|
|
001-36763
|
|
46-3312262
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
3060 Royal Blvd
South, Suite 150
Alpharetta, Georgia
|
|
30022
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
Copies
to:
Harvey Kesner,
Esq.
Arthur S. Marcus,
Esq.
Sichenzia Ross
Ference Kesner LLP
61 Broadway, 32nd
Floor
New York, New York
10006
(212)
930-9700
(212) 930-9725
(fax)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging Growth
Company ☒
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD
Disclosure
On August 29, 2017, Medovex Corp. (the
“Company”) issued a press release related to the
receipt of regulatory approval from Australia's Therapeutic Goals
Administration (TGA) for its DenerveX System (the
“Press
Release”), a copy of which is attached hereto as
Exhibit 99.1.
The information contained in this Current Report
on Form 8-K shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any
filing under the Securities Act of 1933, as amended (the
“Securities
Act”) or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing. The furnishing of the information in
this Current Report on Form 8-K is not intended to, and does not,
constitute a representation that such furnishing is required by
Regulation FD or that the information contained in this Current
Report on Form 8-K constitutes material investor information that
is not otherwise publicly available.
The
Securities and Exchange Commission encourages registrants to
disclose forward-looking information so that investors can better
understand the future prospects of a registrant and make informed
investment decisions. This Current Report on Form 8-K and exhibits
may contain these types of statements, which are
“forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, and which involve
risks, uncertainties and reflect the Registrant’s judgment as
of the date of this Current Report on Form 8-K. Forward-looking
statements may relate to, among other things, operating results and
are indicated by words or phrases such as “expects,”
“should,” “will,” and similar words or
phrases. These statements are subject to inherent uncertainties and
risks that could cause actual results to differ materially from
those anticipated at the date of this Current Report on Form 8-K.
Investors are cautioned not to rely unduly on forward-looking
statements when evaluating the information presented
within.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits.
Exhibit
No.
|
|
Description
|
99.1
|
|
MedoveX Corp. Press
Release dated August 29, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: August
29, 2017
|
MEDOVEX CORPORATION
By: /s/
Jarrett Gorlin
Jarrett Gorlin
Chief Executive Officer
|
|
|